Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements.

TitleChanges in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements.
Publication TypeJournal Article
Year of Publication2022
AuthorsSpetz, J, Hailer, L, Gay, C, Tierney, M, Schmidt, L, Phoenix, B, Chapman, S
JournalJAMA Netw Open
Volume5
Issue5
Paginatione225996
Date Published2022 May 02
ISSN2574-3805
KeywordsBuprenorphine, COVID-19, Humans, Opiate Substitution Treatment, Opioid-Related Disorders, Pandemics
Abstract

This case series examines numbers of US clinicians receiving waivers from the Drug Enforcement Administration allowing them to prescribe buprenorphine for opioid use disorder before and during the COVID-19 pandemic.
DOI10.1001/jamanetworkopen.2022.5996
Alternate JournalJAMA Netw Open
PubMed ID35552728
PubMed Central IDPMC9099425
Grant ListR01 DA047379 / DA / NIDA NIH HHS / United States